3 Founder Led Growth Stocks With High Insider Ownership On The ASX

US manufacturing is slowing while services activity hits multi month highs, and that split is where fast growing stocks with high insider ownership can really matter. Many of these companies lean on services style revenue, and management teams are signalling confidence through meaningful shareholdings. This article highlights three stocks from the Fast Growing Stocks With High Insider Ownership screener that could help you focus on growth where the economy currently shows the most strength.

The three stocks that follow are just a starting sample, and the full screen surfaced around 100 other fast growing companies with high insider ownership that also have compelling stories behind them. If you want to identify and analyze the ideas that fit your own conviction best, head straight into the Fast Growing Stocks With High Insider Ownership screener.

Mesoblast (ASX:MSB)

Mesoblast is a Melbourne based biotech focused on regenerative medicine, using mesenchymal lineage cell therapies to target severe inflammatory and cardiovascular diseases. Its strongest link to the Fast Growing Stocks With High Insider Ownership theme is the product pipeline built around Remestemcel L and partnered programs like MPC 150/25 and Ryoncil, which are development stage biologic therapies aimed at large, treatment resistant conditions. The company currently generates about $65 million from developing its cell technology platform for commercialization and has a market value of roughly A$3.1b.

Mesoblast provides exposure to a late stage cell therapy pipeline that includes an FDA approved product in Ryoncil, as well as multiple Phase III programs in chronic low back pain and heart failure that are aligned with the screener’s growth focus. At the same time, Mesoblast is still unprofitable and relies heavily on external funding, so the story depends on clinical readouts, regulatory decisions and broader adoption of high cost therapies over the coming years. For investors seeking a live example of how management confidence, analyst optimism and real world catalysts can align in a single stock, Mesoblast is a company that may warrant closer consideration.

Mesoblast’s late stage pipeline, insider backing and early revenue can look like only half the picture. See how the analyst forecasts for Mesoblast frames the potential growth path and the key hurdle that could flip the story.

Build your own fast growth and insider backed shortlist

Mesoblast and the other two stocks in this article all surfaced from a single screen, but the real advantage comes from shaping the filters around what matters most to you. Use our Screener to mix growth, insider ownership, valuation and risk checks into your own shortlist, or lean on any of our curated Investing Ideas for ready made starting points.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals is a North Melbourne based radiopharmaceutical company that develops and sells precision imaging agents and cancer therapies, with its late stage TLX591 prostate cancer program providing the strongest direct link to the Fast Growing Stocks With High Insider Ownership theme. The business currently leans on commercial precision medicine products such as Illuccix and Gozellix, with around $705 million of revenue from Precision Medicine, about $277 million from Manufacturing Solutions and inter segment eliminations of roughly $96 million. Telix has a market value of about A$5.3b.

Telix is drawing attention because it already earns meaningful revenue from Illuccix and Gozellix while pushing TLX591 through a Phase 3 trial that could reshape its prostate cancer franchise. Recent updates point to 22% revenue growth in the first half of 2026, expanding EBITDA and progress across multiple Phase 3 programs, which fits the screener’s focus on companies where growth expectations are backed by active execution from management. The flip side is that Telix still runs on slim margins, depends heavily on successful trial readouts and carries funding and regulatory risks that could quickly change sentiment if results or approvals disappoint. Investors who want to understand how this mix of commercial cash flow, high stakes trials and a premium valuation fits together may find that Telix rewards closer study.

Telix appears to be a radiopharma growth story with real cash flow already in play. The real question is how the mix of Illuccix, Gozellix and TLX591 stacks up once you see the full analysis report for Telix Pharmaceuticals

Lindian Resources (ASX:LIN)

Lindian Resources is a Perth based explorer focused on rare earths, bauxite and gold across Tanzania, Guinea, Malawi, Australia and Singapore, with the Kangankunde Rare Earths project in Malawi as its flagship asset and clearest link to the Fast Growing Stocks With High Insider Ownership theme. The company is still in the development phase and does not yet break out meaningful revenue by business line or region. Lindian currently carries a market value of about A$1.4b.

Lindian Resources may appeal if you want early exposure to rare earths, with Kangankunde in Malawi and the SARECO processing facility in Kazakhstan both working toward first production and processing around Q4 2026. Current revenue is under A$1 million, the company remains loss making and funding is tied to higher risk external capital, which raises dilution risk. The share price has also been volatile and the board has limited independence. This creates a higher risk story where successful execution on mining, processing and a new Singapore sales hub could be rewarded, but where any slip in timelines or costs would matter quickly.

Lindian Resources is an early stage rare earths story with timing risk, but the real question is how Kangankunde and SARECO could reshape that profile once you have the full analysis report for Lindian Resources.

Seeking Fresh Alternatives Before They Fly

Some of the sharpest breakouts start quietly while attention is caught elsewhere. Consider using these fresh screens before the momentum is gone and the data stops mattering, and act only if it fits your own approach.

• Spot resilient cash generators before they are widely talked about by scanning a curated list of solid balance sheet and fundamentals (20 results) that keeps options open if conditions change quickly.
• Look for potential income opportunities from companies built around steady payouts by checking a focused pool of 6 dividend fortresses while yields and prices still look aligned.
• Review a filtered group of 32 elite gold producer stocks to explore the next resources story before gold sentiment swings and later entries feel less timely.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com